First Manhattan CO. LLC. Purchases 27,861 Shares of IQVIA Holdings Inc. $IQV

First Manhattan CO. LLC. increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.6% in the 1st quarter, HoldingsChannel reports. The firm owned 233,412 shares of the medical research company’s stock after acquiring an additional 27,861 shares during the quarter. First Manhattan CO. LLC.’s holdings in IQVIA were worth $41,151,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. American National Bank & Trust bought a new stake in IQVIA during the first quarter worth about $26,000. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after acquiring an additional 131 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in shares of IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC bought a new position in shares of IQVIA in the first quarter worth about $33,000. Finally, ST Germain D J Co. Inc. lifted its holdings in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on IQV. Mizuho increased their target price on shares of IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Truist Financial increased their target price on shares of IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. Robert W. Baird increased their target price on shares of IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a report on Wednesday, July 23rd. Evercore ISI upped their price objective on IQVIA from $170.00 to $180.00 and gave the company an “outperform” rating in a research note on Wednesday, July 9th. Finally, Barclays upped their price objective on IQVIA from $165.00 to $185.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $228.62.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,800 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Keriann Cherofsky sold 549 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $190.71 on Monday. The company has a market capitalization of $32.42 billion, a P/E ratio of 27.60, a P/E/G ratio of 2.09 and a beta of 1.32. The business has a 50 day moving average of $177.04 and a 200-day moving average of $167.51. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.